Vortex Biosciences is a US-based cancer diagnostic company, developing a novel liquid biopsy automated instrument (VTX-1) and microfluidic cartridge for the isolation of circulating tumour cells from whole blood without the need for any pre-treatment.
The label-free technology enables high purity and collection efficiency of intact circulating tumour cells in less than an hour. The technology enables researchers and clinicians to non-invasively capture, identify, analyse and enumerate tumour cells for use in downstream clinical applications such as cancer diagnosis and monitoring, personalised medicine, drug development, and cancer research in the estimated US$22 billion liquid biopsy market (JP Morgan Liquid Biopsy Report – 27 May, 2015).
See our Annual Report for more information
Diagnostics – Cancer
Menlo Park, California, US